COHERUS BIOSCIENCES INC (CHRS)
US19249H1032 - Common Stock
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...
Commit To Purchase Coherus BioSciences At $2, Earn 32.2% Annualized Using Options
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of...
Commit To Purchase Coherus BioSciences At $2, Earn 42.6% Annualized Using Options
Why Coherus Biosciences Stock Tumbled on Thursday
The company fell well short of expectations for its fourth quarter.
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and...
Coherus Completes Divestiture of Ophthalmology Franchise
Coherus Completes Divestiture of Ophthalmology Franchise
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY,...
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety...
Why Coherus BioSciences Stock Jumped Today
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan...
Why Coherus BioSciences Stock Is Sinking Today
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Why Coherus Biosciences Popped Today
Coherus is divesting its non-core ophthalmology franchise.
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price.
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news.
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!
Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal
Sandoz (SDZNY) has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI from Coherus BioSciences (CHRS) for an upfront cash purchase payment of $170 million, along with an..
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY,...